Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor:

www.clinical-genitourinary-cancer.com/article/S155...

@drkarinetawagi.bsky.social
@vadimkoshkin.bsky.social
@erplimackmd.bsky.social
Peter H. O’Donnel

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines This overview of the 2025 European Association of Urology guidelines offers valuable insights into the risk factors, diagnosis, classification, treatment, and follow-up of muscle-invasive bladder canc...

European Association of Urology Guidelines on Muscle-invasive and Metastatic #BladderCancer : Summary of the 2025 Guidelines

www.europeanurology.com/article/S030...

Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single... Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen.

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer

www.thelancet.com/journals/lan...

Results support further investigation of this chemotherapy-free triplet approach as a potential tx option

@erikahamilton9.bsky.social

Advancing breast cancer treatment in the era of molecular diagnostics Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations, marking a significant step forward in cancer care,...

Advancing breast cancer treatment in the era of molecular diagnostics

thebreastonline.com/article/S096...

Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer - Breast Cancer Research and Treatment Purpose Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant e...

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive #BreastCancer

link.springer.com/article/10.1...

Findings suggest that prolonged NET may lead to more substantial tumor downstaging

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial - Nature Cancer Galsky and colleagues report the results of a phase 1 clinical trial of anti-programmed cell death protein 1 ligand 1 atezolizumab in combination with PGV001, a personalized neoantigen vaccine, in par...

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer

www.nature.com/articles/s43...

Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer

NEWS FROM INDUSTRY

Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial - Prostate Cancer and Prostatic Dise... Prostate Cancer and Prostatic Diseases - Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II...

Addition of zoledronic acid to enzalutamide and ADT in metastatic hormone-sensitive prostate cancer: BONENZA

www.nature.com/articles/s41...

Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth f...

PALMIRA: Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With HR+/HER 2– Advanced #BreastCancer

ascopubs.org/doi/full/10....

Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth f...

2L Endocrine Therapy With or Without Palbociclib Rechallenge in HR+/Human Epidermal Growth Factor Receptor 2–Negative Advanced #BreastCancer: PALMIRA Trial

ascopubs.org/doi/full/10....

Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group Clinical prediction models are increasingly used to guide treatment in patients with early breast cancer. The Danish Breast Cancer Group (DBCG) has de…

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early #BreastCancer 🇩🇰

sciencedirect.com/science/arti...

Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy

Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review Despite its radioresistant reputation, renal cell carcinoma (RCC) is sensitive to high dose per fraction stereotactic ablative body radiotherapy (SABR…

Stereotactic Body Radiation☢️Therapy Alone or in Combination with Immunotherapy in #KidneyCancer

sciencedirect.com/science/arti...

findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.

Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC Leptomeningeal metastases (LM) in patients with breast cancer (BC) are associated with a dismal prognosis. We explored clinical characteristics and prognostic factors in patients with BC and LM in the...

Clinical characteristics & prognostic factors in pts with breast cancer and leptomeningeal metastases

www.thebreastonline.com/article/S096...

Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation

Selective Elimination of Breast Surgery for Invasive Breast Cancer This nonrandomized trial examines 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients with breast cancer selected with image-guided vacuum assisted biopsy.

Selective Elimination of Breast Surgery for Invasive #BreastCancer out on JAMA Oncology

jamanetwork.com/journals/jam...

Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.

Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer This study analyzed the correlation of invasive disease-free survival (iDFS) and overall survival (OS) in the adjuvant HR+/HER2– early breast cancer (EBC) setting using real-world patient data. The r....

Correlation analysis of invasive disease-free survival and OS in a real-world population of patients w/ HR+/HER2– early #BreastCancer

acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma This cohort study of US adults with metastatic clear cell renal cell carcinoma examines changes in forms of treatment used following the approval of immune-checkpoint inhibitor combinations by the US ...

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma

jamanetwork.com/journals/jam...

Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval.
#KidneyCancer

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial Immune checkpoint inhibitors (ICI) have been investigated in combination with preoperative chemotherapy in early-stage triple negative breast cancer (TNBC) and in estrogen receptor-positive, human epi...

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial #BreastCancer

thegreenjournal.com/article/S016...

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians The treatment landscape for patients with advanced urothelial carcinoma (UC) has evolved rapidly in recent years. In current guidelines, combination t…

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians

sciencedirect.com/science/arti...

Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer

Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial - Nature Communications Angioscore is a transcriptome based predicter of treatment response in clear cell renal cell carcinoma. Here, the authors use deep learning to infer the Angioscore from histopathology slides using cli...

Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial

nature.com/articles/s41...

model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer

Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer - Breast Cancer Research and Treatment Background Triple-negative breast cancer (TNBC) patients are at increased risk for recurrence compared to other subtypes of breast cancer. Previous evidence showed that adiposity may contribute to wor...

Body composition as a potential biomarker of recurrence risk in patients with triple-negative #BreastCancer

link.springer.com/article/10.1...

Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts PURPOSEThe COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial ...

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

ascopubs.org/doi/full/10....

The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherap...

Safety & Efficacy of Neoadjuvant Durvalumab + Gemcitabine/Cisplatin or Carboplatin in Patients W/ Operable High-Risk Upper Tract Urothelial Carcinoma

ascopubs.org/doi/10.1200/...

Although the primary endpoint was not met, the combination therapy showed promising downstaging effects
#BladderCancer

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY

aacrjournals.org/cancerdiscov...

The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY

aacrjournals.org/cancerdiscov...

The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with im...

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

www.tandfonline.com/doi/full/10....

This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes.
#KidneyCancer

CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization
aacrjournals.org/clincancerre...

findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer

OS analysis of Young-PEARL out on Lancet Oncology:
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer

www.sciencedirect.com/science/arti...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer PURPOSETo assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for earl...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early #BreastCancer

ascopubs.org/doi/10.1200/...

Findings suggest that iDFS w/ sufficient follow-up is a reliable surrogate for OS in neoadjuvant RCTs, except in HR+ #BreastCancer

@oncoalert.bsky.social 🚨

Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer This cohort study examines interruption and resumption of endocrine therapy among women with breast cancer who became pregnant.

Endocrine Therapy💊 Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer out on JAMA Oncology

jamanetwork.com/journals/jam...

Study highlights the need for better re-engagement of #BreastCancer survivors in guideline-based care after pregnancy🤰

Prolonged time to breast cancer surgery and the risk of metastasis

https://buff.ly/3X8UgHN

Study highlights importance of timely surgical treatment for #BreastCancer , as delaying surgery increases the risk of metastasis